Serological Assays for the Detection and Characterization of Influenza Viruses
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
CDC OFFICE OF ACQUISITION SERVICES
Contract Value
Not provided
Codes & Classification
Solicitation Number
75D30125R73235
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
Q301
Additional Details
The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services has issued an active solicitation titled "Serological Assays for the Detection and Characterization of Influenza Viruses" (Procurement Identifier: 75D30125R73235). This procurement seeks to engage qualified contractors in the manufacturing and provision of in-vitro diagnostic substances, specifically serological assays, to support the detection and characterization of influenza viruses. The intended outcome is to enhance the CDC’s capacity for influenza surveillance, research, and public health response by acquiring reliable and validated serological assay solutions.
The scope of this solicitation encompasses the development, production, and delivery of serological assays that meet rigorous standards for sensitivity, specificity, and reproducibility in detecting and characterizing various influenza virus strains. Contractors are expected to provide assays that are suitable for use in laboratory settings, supporting the CDC’s ongoing efforts in monitoring influenza activity, identifying emerging strains, and informing vaccine development and public health interventions. Key requirements include compliance with the North American Industry Classification System (NAICS) code 325413, which pertains to In-Vitro Diagnostic Substance Manufacturing, and alignment with Product Service Code Q301, indicating a focus on medical laboratory services.
The place of performance for this contract is Atlanta, Georgia, where the CDC is headquartered. The solicitation is managed by the CDC Office of Acquisition Services, a federal office responsible for procuring goods and services to support the agency’s mission. Interested parties should note that Jennifer Gartzke has been reinstated as the primary point of contact for this opportunity; she can be reached at [email protected] for further inquiries or clarifications.
This solicitation is currently active, with a post date of November 12, 2025, and a response deadline of February 15, 2026. Contractors are encouraged to review the attached SF30 amendment for additional details regarding the reopening of the solicitation and source selection activities. The opportunity is listed on SAM.gov under Opportunity ID f2c10f433ad1479e9f5f46649b15915c, where ten attachments provide supplementary information pertinent to the solicitation.
No specific set-aside requirements or special considerations have been indicated in the provided notice. Contractors specializing in in-vitro diagnostic substance manufacturing, with proven expertise in serological assay development for influenza viruses, are well-positioned to respond to this solicitation. The CDC’s commitment to advancing public health through robust influenza surveillance underscores the importance of this procurement, and successful contractors will play a critical role in supporting national and global influenza preparedness efforts.
For comprehensive details, interested vendors should consult the official solicitation documents and attachments available via the SAM.gov opportunity listing.
Documents10